- Pretreatment risk factors for parametrial involvement in FIGO stage IB1 cervical cancer
-
Yamazaki H, Todo Y, Okamoto K, Yamashiro , Kato H
- KMID: 2345915
- J Gynecol Oncol.
- 2015 Oct;26(4):255-261.
- doi: 10.3802/jgo.2015.26.4.255
OBJECTIVE: All patients with stage IB1 cervical cancer do not need to undergo parametrectomy. Some low-risk criteria for parametrial involvement (PI) have been proposed based on pathological findings. The aim... -
- CITED
-
- Close
- SHARE
-
- Close
- Prognostic value of preoperative intratumoral FDG uptake heterogeneity in early stage uterine cervical cancer
-
Chung HH, Kang SY, Ha S, Kim JW, Park NH, Song YS, Cheon GJ
- KMID: 2360245
- J Gynecol Oncol.
- 2016 Mar;27(2):e15.
- doi: 10.3802/jgo.2016.27.e15
OBJECTIVE: We investigated the prognostic value of intratumoral [18F]fluorodeoxyglucose (FDG) uptake heterogeneity (IFH) derived from positron emission tomography/computed tomography (PET/CT) in patients with cervical cancer. METHODS: Patients with uterine cervical cancer... -
- CITED
-
- Close
- SHARE
-
- Close
- Transactivation of bad by vorinostat-induced acetylated p53 enhances doxorubicin-induced cytotoxicity in cervical cancer cells
-
Lee SJ, Hwang SO, Noh EJ, Kim DU, Nam M, Kim JH, Nam JH, Hoe KL
- KMID: 2155341
- Exp Mol Med.
- 2014 Feb;46(2):e76.
- doi: 10.1038/emm.2013.149
Vorinostat (VOR) has been reported to enhance the cytotoxic effects of doxorubicin (DOX) with fewer side effects because of the lower DOX dosage in breast cancer cells. In this study,... -
- CITED
-
- Close
- SHARE
-
- Close
